Sentinox: meta-analysis of COVID-19 studies

All studies   Serious outcomes   Viral clearance   RCTs   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies 67% 1 57 Improvement, Studies, Patients Relative Risk Viral clearance 29% 1 49 RCTs 67% 1 57 Early 67% 1 57 Sentinox for COVID-19 c19early.org December 2025 Favorssentinox Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Panatto (RCT) 67% 0.33 [0.06-1.83] progression 2/38 3/19 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.21 Early treatment 67% 0.33 [0.06-1.83] 2/38 3/19 67% lower risk All studies 67% 0.33 [0.06-1.83] 2/38 3/19 67% lower risk 1 sentinox COVID-19 study c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.21 Effect extraction pre-specified(most serious outcome) Favors sentinox Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Panatto (RCT) 67% 0.33 [0.06-1.83] progression 2/38 3/19 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.21 Early treatment 67% 0.33 [0.06-1.83] 2/38 3/19 67% lower risk All studies 67% 0.33 [0.06-1.83] 2/38 3/19 67% lower risk 1 sentinox COVID-19 serious outcome c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.21 Effect extraction pre-specified(most serious outcome) Favors sentinox Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Panatto (RCT) 29% 0.71 [0.54-0.93] viral+ 34 (n) 15 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.012 Early treatment 29% 0.71 [0.54-0.93] 34 (n) 15 (n) 29% lower risk All studies 29% 0.71 [0.54-0.93] 34 (n) 15 (n) 29% lower risk 1 sentinox COVID-19 viral clearance result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.012 Favors sentinox Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Panatto (RCT) 67% 0.33 [0.06-1.83] progression 2/38 3/19 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.21 Early treatment 67% 0.33 [0.06-1.83] 2/38 3/19 67% lower risk All studies 67% 0.33 [0.06-1.83] 2/38 3/19 67% lower risk 1 sentinox COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.21 Effect extraction pre-specified(most serious outcome) Favors sentinox Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Panatto (RCT) 67% 0.33 [0.06-1.83] progression 2/38 3/19 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.21 Early treatment 67% 0.33 [0.06-1.83] 2/38 3/19 67% lower risk All studies 67% 0.33 [0.06-1.83] 2/38 3/19 67% lower risk 1 sentinox COVID-19 peer reviewed studies c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.21 Effect extraction pre-specified(most serious outcome) Favors sentinox Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Panatto (RCT) 67% 0.33 [0.06-1.83] progression 2/38 3/19 Improvement, RR [CI] Treatment Control Panatto (RCT) 29% 0.71 [0.54-0.93] viral+ 34 (n) 15 (n) Panatto (RCT) 30% 0.70 [0.56-0.88] viral+ 34 (n) 15 (n) Sentinox COVID-19 outcomes c19early.org December 2025 Favors sentinox Favors control